Alterations in CD46-mediated Tr1 Regulatory T Cells in Patients with Multiple Sclerosis

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2006 Nov 14

PMID 17099776

Citations 128

Authors

Anne L Astier

Gregory Meiffren

Samuel Freeman

David A Hafler

Affiliations

Soon will be listed here.

Abstract

Loss of Treg function appears to be a critical factor in the pathogenesis of human autoimmune diseases. Attention has focused on defects of CD4(+)CD25(high) Tregs, and techniques have been developed to determine their function. In contrast, the role of Tr1 regulatory T cells, which secrete the antiinflammatory cytokine IL-10, in autoimmune disease has not been well assessed. CD46 is a newly defined costimulatory molecule for T cell activation, and CD46-costimulated human T cells induce a Tr1 Treg phenotype with considerable amounts of IL-10 secretion. Here, we examined the role of Tr1 cells in patients with multiple sclerosis (MS) by stimulating CD4(+) T cells with anti-CD3 and -CD46 mAbs and measuring IL-10 secretion. There were striking defects in the induction of Tr1 cells with CD46 costimulation as measured by IL-10 but not IFN-gamma secretion in patients with MS compared with healthy subjects. This loss of Tr1 cell-associated IL-10 secretion was specific to CD46 and not CD28 costimulation and was associated with an altered regulation of the CD46-Cy2 isoform that differentially regulates T cell function in a CD46-transgenic murine model. These data demonstrate a second major Treg defect in human autoimmune disease associated with the CD46 pathway.

Citing Articles

Proteolytic shedding of CD46 from human hepatocytes indicates liver stress.

Kupke P, Yang Zhou J, Glehr G, Riquelme P, Scheibert L, Adenugba A Heliyon. 2024; 10(23):e40841.

PMID: 39698100 PMC: 11652852. DOI: 10.1016/j.heliyon.2024.e40841.

Re-establishing immune tolerance in multiple sclerosis: focusing on novel mechanisms of mesenchymal stem cell regulation of Th17/Treg balance.

Hu H, Li H, Li R, Liu P, Liu H J Transl Med. 2024; 22(1):663.

PMID: 39010157 PMC: 11251255. DOI: 10.1186/s12967-024-05450-x.

DUSP6 deletion protects mice and reduces disease severity in autoimmune arthritis.

Laragione T, Harris C, Rice N, Gulko P iScience. 2024; 27(6):110158.

PMID: 38974475 PMC: 11225809. DOI: 10.1016/j.isci.2024.110158.

The beneficial role of autophagy in multiple sclerosis: Yes or No?.

Al-Kuraishy H, Jabir M, Al-Gareeb A, Saad H, El-Saber Batiha G, Klionsky D Autophagy. 2023; 20(2):259-274.

PMID: 37712858 PMC: 10813579. DOI: 10.1080/15548627.2023.2259281.

Complement: Functions, location and implications.

Kareem S, Jacob A, Mathew J, Quigg R, Alexander J Immunology. 2023; 170(2):180-192.

PMID: 37222083 PMC: 10524990. DOI: 10.1111/imm.13663.

References

Ludford-Menting M, Thomas S, Crimeen B, Harris L, Loveland B, Bills M . A functional interaction between CD46 and DLG4: a role for DLG4 in epithelial polarization. J Biol Chem. 2001; 277(6):4477-84. DOI: 10.1074/jbc.M108479200. View

Grossman W, Verbsky J, Tollefsen B, Kemper C, Atkinson J, Ley T . Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood. 2004; 104(9):2840-8. DOI: 10.1182/blood-2004-03-0859. View

Marie J, Astier A, Rivailler P, Rabourdin-Combe C, Wild T, Horvat B . Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat Immunol. 2002; 3(7):659-66. DOI: 10.1038/ni810. View

Kemper C, Chan A, Green J, Brett K, Murphy K, Atkinson J . Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature. 2003; 421(6921):388-92. DOI: 10.1038/nature01315. View

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

Viglietta V, Baecher-Allan C, Weiner H, Hafler D . Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004; 199(7):971-9. PMC: 2211881. DOI: 10.1084/jem.20031579. View

Cattaneo R . Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet. J Virol. 2004; 78(9):4385-8. PMC: 387720. DOI: 10.1128/jvi.78.9.4385-4388.2004. View

Russell S . CD46: a complement regulator and pathogen receptor that mediates links between innate and acquired immune function. Tissue Antigens. 2004; 64(2):111-8. DOI: 10.1111/j.1399-0039.2004.00277.x. View

Adorini L . Immunotherapeutic approaches in multiple sclerosis. J Neurol Sci. 2004; 223(1):13-24. DOI: 10.1016/j.jns.2004.04.014. View

10.

Kozovska M, Hong J, Zang Y, Li S, Rivera V, Killian J . Interferon beta induces T-helper 2 immune deviation in MS. Neurology. 1999; 53(8):1692-7. DOI: 10.1212/wnl.53.8.1692. View

11.

Wang G, Liszewski M, Chan A, Atkinson J . Membrane cofactor protein (MCP; CD46): isoform-specific tyrosine phosphorylation. J Immunol. 2000; 164(4):1839-46. DOI: 10.4049/jimmunol.164.4.1839. View

12.

Astier A, Trescol-Biemont M, Azocar O, Lamouille B, Rabourdin-Combe C . Cutting edge: CD46, a new costimulatory molecule for T cells, that induces p120CBL and LAT phosphorylation. J Immunol. 2000; 164(12):6091-5. DOI: 10.4049/jimmunol.164.12.6091. View

13.

Bach J . Non-Th2 regulatory T-cell control of Th1 autoimmunity. Scand J Immunol. 2001; 54(1-2):21-9. DOI: 10.1046/j.1365-3083.2001.00945.x. View

14.

Clerici M, Saresella M, Trabattoni D, Speciale L, Fossati S, Ruzzante S . Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. J Neuroimmunol. 2001; 121(1-2):88-101. DOI: 10.1016/s0165-5728(01)00431-3. View

15.

Zaffran Y, Destaing O, Roux A, Ory S, Nheu T, Jurdic P . CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase. J Immunol. 2001; 167(12):6780-5. DOI: 10.4049/jimmunol.167.12.6780. View

16.

Sanchez A, Feito M, Rojo J . CD46-mediated costimulation induces a Th1-biased response and enhances early TCR/CD3 signaling in human CD4+ T lymphocytes. Eur J Immunol. 2004; 34(9):2439-48. DOI: 10.1002/eji.200324259. View

17.

Hohlfeld R, Wekerle H . Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2:14599-606. PMC: 521993. DOI: 10.1073/pnas.0404874101. View

18.

Christen U, von Herrath M . Initiation of autoimmunity. Curr Opin Immunol. 2004; 16(6):759-67. DOI: 10.1016/j.coi.2004.09.002. View

19.

Antel J, Freedman M, Brodovsky S, Francis G, Duquette P . Activated suppressor cell function in severely disabled patients with multiple sclerosis. Ann Neurol. 1989; 25(2):204-7. DOI: 10.1002/ana.410250219. View

20.

Russell S, Loveland B, Johnstone R, Thorley B, McKenzie I . Functional characterisation of alternatively spliced CD46 cytoplasmic tails. Transplant Proc. 1992; 24(5):2329-30. View